Leonard JP et al. -The effect of adding bortezomib to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in previously untreated patients with non–germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL) was determined.In the current study it was shown that patients with non-GCB DLBCL had favorable responses to R-CHOP that was not significantly improved by adding bortezomib.